Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atropine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : $45.8 million
Deal Type : Acquisition
Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets
Details : The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approv...
Brand Name : Atropine-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2022
Lead Product(s) : Atropine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : $45.8 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
